Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Capital Expenditures: 2019-2024

Historic Capital Expenditures for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $3.8 million.

  • 4D Molecular Therapeutics' Capital Expenditures fell 105.12% to -$91,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 54.08%. This contributed to the annual value of $3.8 million for FY2024, which is 36.63% up from last year.
  • 4D Molecular Therapeutics' Capital Expenditures amounted to $3.8 million in FY2024, which was up 36.63% from $2.8 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Capital Expenditures peaked at $11.5 million during FY2022, and registered a low of $1.0 million during FY2020.
  • Moreover, its 3-year median value for Capital Expenditures was $3.8 million (2024), whereas its average is $6.0 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 811.00% in 2021, then plummeted by 75.98% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Capital Expenditures (Yearly) stood at $1.0 million in 2020, then surged by 811.00% to $9.1 million in 2021, then climbed by 26.63% to $11.5 million in 2022, then plummeted by 75.98% to $2.8 million in 2023, then skyrocketed by 36.63% to $3.8 million in 2024.